Recent studies conducted by researchers from the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Spain have shed new light on clonal hematopoiesis and its treatment with the anti-inflammatory drug colchicine. Clonal hematopoiesis, which involves blood-forming stem cells acquiring genetic mutations and proliferating, has been identified as a risk factor for atherosclerosis, the main cause of cardiovascular diseases. This discovery opens up the possibility of developing personalized treatments for patients in the future.
One of the studies published in Nature Medicine in August 2024 revealed clonal hematopoiesis as a new risk factor for atherosclerosis, indicating that individuals with this condition are more likely to develop plaques in their arteries. The second study, published in the European Heart Journal, suggested that colchicine could be a key component in personalized treatment plans for individuals with clonal hematopoiesis linked to mutations in the TET2 gene. These findings have significant implications for understanding the relationship between clonal hematopoiesis and cardiovascular disease.
Jose J. Fuster, PhD, lead author of both studies, explained that clonal hematopoiesis occurs when genetic mutations in blood cells affect their function and increase the risk of cardiovascular problems. The research clarifies the link between clonal hematopoiesis and atherosclerosis, showing that the former contributes to the development of the latter. Increased clonal hematopoiesis was associated with greater atherosclerosis, emphasizing the need for further research to understand the mechanisms underlying this relationship.
Individuals with clonal hematopoiesis may experience an increased risk of arterial plaques due to the production of inflammatory mediators by mutated blood cells. The research challenges the perception that clonal hematopoiesis mutations only affect older adults, suggesting that they could play a role in the development of heart disease and cancer at a younger age. While identifying clonal hematopoiesis as a potent cardiovascular risk factor, there is currently no evidence-based intervention to mitigate this risk, highlighting the need for personalized treatment strategies tailored to specific mutations.
Fuster recommends focusing on blocking the effects of mutations linked to clonal hematopoiesis to prevent cardiovascular disease. Ongoing research aims to develop personalized strategies for individuals carrying these mutations to reduce their risk of heart disease. Screening for these mutations could potentially help assess long-term health risks and enable early intervention through lifestyle changes or targeted treatments for high-risk individuals. Understanding the connection between clonal hematopoiesis and atherosclerosis could pave the way for innovative therapies to lower the risk of cardiovascular disease in affected individuals.
